Pharmacogenetics of controlled ovarian hyperstimulation: time to corroborate the clinical utility of FSH receptor genetic markers

Author： Morón Francisco Jesús   Ruiz Agustín  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.11, Iss.11, 2010-11, pp. : 1613-1618

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenetics of controlled ovarian hyperstimulation

By de Castro Francisco   Morón Francisco J   Montoro Luis   Real Luis M   Ruiz Agustín  

Pharmacogenomics, Vol. 6, Iss. 6, 2005-09 ,pp. : 629-637

Future Medicine

Access to resources Recommend Favorite

Modeling Follicle Stimulating Hormone (FSH) Levels in Serum for Controlled Ovarian Hyperstimulation II: The Underlying Mechanisms

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 3, 2012-03 ,pp. : 444-453

Bentham Science Publishers

Access to resources Recommend Favorite

Controlled ovarian hyperstimulation pharmacogenetics: a simplified model to genetically dissect estrogen-related diseases

By Morón Francisco Jesús   Galán José Jorge   Ruiz Agustín  

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 775-785

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics: global clinical markers

By Marsh Sharon  

Pharmacogenomics, Vol. 9, Iss. 4, 2008-04 ,pp. : 371-373

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping

By Innocenti Federico   Ratain Mark J  

Pharmacogenomics, Vol. 7, Iss. 8, 2006-12 ,pp. : 1211-1221

Future Medicine

Access to resources Recommend Favorite